

RECEIVED

Page 1 of 4

JUN 2 2001

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UTSD:674US/SLH

09/782,953

TECH CENTER 1600/2900

List of Patents and Publications for Applicant's

Applicant

R. Sanders Williams and Beverly Rothermel

INFORMATION DISCLOSURE STATEMENT

Filing Date:

February 13, 2001

Group:

1645

(Use several sheets if necessary)

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>Swl</i>	C1	Beals <i>et al.</i> , "Nuclear localization of NF-Atc by a calcineurin-dependent, cyclosporin-sensitive intramolecular interaction," <i>Genes Dev.</i> , 11:824-834, 1997.
<i>Swl</i>	C2	Chin <i>et al.</i> , "A calcineurin-dependent transcriptional pathway controls skeletal muscle fiber type," <i>Genes Dev.</i> , 12:2499-2509, 1998.
<i>Swl</i>	C3	Crabtree, "Generic signals and specific outcomes: signaling through Ca ²⁺ , calcineurin, and NF-AT," <i>Cell</i> , 96:611-614, 1999.
<i>Swl</i>	C4	Ding <i>et al.</i> , "Pressure overload induces severe hypertrophy in mice treated with cyclosporine, an inhibitor of calcineurin," <i>Circ Res.</i> , 84:729-734, 1999.
<i>Swl</i>	C5	Dunn <i>et al.</i> , "Calcineurin is required for skeletal muscle hypertrophy," <i>J Biol Chem.</i> , 274:21908-21912, 1999.
<i>Swl</i>	C6	Eto <i>et al.</i> , "Calcineurin is activated in rat hearts with physiological left ventricular hypertrophy induced by voluntary exercise training," <i>Circulation</i> , 101:2134-2137, 2000.
<i>Swl</i>	C7	Friddle <i>et al.</i> , "Expression profiling reveals distinct sets of genes altered during induction and regression of cardiac hypertrophy," <i>Proc. Natl. Acad. Sci. USA</i> , 97:6745-6750, 2000.
<i>Swl</i>	C8	Fuentes <i>et al.</i> , "Genomic organization, alternative splicing, and expression patterns of the DSCR1 (Down syndrome candidate region 1) gene," <i>Genomics</i> , 44:358-361, 1997.

25030842.1

EXAMINER:

R. Sanders Williams

DATE CONSIDERED:

1-17-2003

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

RECEIVED
Page 2 of 4

Form PTO-1449 (modified)

Atty. Docket No.
UTSD:674US/SLHSerial No.
09/782,953 JUN 22 2001

**List of Patents and Publications for Applicant's
INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

Applicant
R. Sanders Williams and Beverly Rothermel
TECH CENTER 1600/2900Filing Date:
February 13, 2001Group:
1645U.S. Patent Documents
*See Page 1*Foreign Patent Documents
*See Page 1*Other Art
*See Page 1***Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

Exam. Init.	Ref. Des.	Citation
<i>SWL</i>	C9	Fuentes <i>et al.</i> , "A new human gene from the Down syndrome critical region encodes a proline-rich protein highly expressed in fetal brain and heart," ABSTRACT, <i>Hum. Mol. Genet.</i> , 4:1935-1944, 1995.
<i>SWL</i>	C10	Graef <i>et al.</i> , "L-type calcium channels and GSK-3 regulate the activity of NF-Atc4 in hippocampal neurons," <i>Nature</i> , 401:703-8, 1999.
<i>SWL</i>	C11	Grayson <i>et al.</i> , "Synergistic interactions between heterologous upstream activation elements and specific TATA sequences in a muscle-specific promoter," <i>Mol Cell Biol.</i> , 15(4):1870-1878, 1995.
<i>SWL</i>	C12	Grayson <i>et al.</i> , "Collaborative interactions between MEF-2 and Sp1 in muscle-specific gene regulation," <i>J. Cell. Biochem.</i> , 70:366-375, 1998.
<i>SWL</i>	C13	Ho <i>et al.</i> , "NFATc3, a lymphoid-specific NFATc family member that is calcium-regulated and exhibits distinct DNA binding specificity," <i>J. Biol. Chem.</i> , 270(34):19898-19907, 1995.
<i>SWL</i>	C14	Ho <i>et al.</i> , "Activation protein 1-dependent transciptional activation of interleukin 2 gene by Ca ²⁺ /calmodulin kinase type IV/Gr," ABSTRACT, <i>J. Exp. Med.</i> , 184:101-112, 1996.
<i>SWL</i>	C15	Hoey <i>et al.</i> , "Isolation of two new membes of the NF-AT gene family and functional characterization of the NF-AT proteins," ABSTRACT, <i>Immunity</i> , 2:461-472, 1995.
<i>SWL</i>	C16	Kashishian <i>et al.</i> , "AKAP79 inhibits calcineurin through a site distinct from the immunophilin-binding region," <i>J. Biol. Chem.</i> , 273:27412-27419, 1998.
<i>SWL</i>	C17	Kingsbury and Cunningham, "A conserved family of calcineurin regulators," <i>Genes Dev.</i> , 14(13):1595-1604, 2000.
<i>SWL</i>	C18	Klauck <i>et al.</i> , "Coordination of three signaling enzymes by AKAP79, a mammalian scaffold protein," <i>Science</i> , 271:1589-1592, 1996.
<i>SWL</i>	C19	Klee <i>et al.</i> , "Regulation of the calmodulin-stimulated protein phosphatase, calcineurin," <i>J. Biol. Chem.</i> , 273(22):13367-13370, 1998.
<i>SWL</i>	C20	Lai <i>et al.</i> , "Cain, a novel physiologic protein inhibitor of calcineurin," <i>J. Biol. Chem.</i> , 273(29):18325-18331, 1998.
<i>SWL</i>	C21	Liu <i>et al.</i> , "Cyclosporin A-sensetive induction of the Epstein-Barr virus lytic switch is mediated via a novel pathway involving a MEF2 family member," <i>EMBO J.</i> , 16:143-153, 1997.

25030842.1

EXAMINER:

DATE CONSIDERED:

1-17-2003

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

RECEIVED
Page 3 of 4

Form PTO-1449 (modified)

Atty. Docket No.
UTSD:674US/SLHSerial No. JUN 2 2 2001
09/782,953

O I P E S C T S
JUN 19 2001
U.S. PATENT & TRADEMARK OFFICE
List of Patents and Publications for Applicant's
INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

Applicant
R. Sanders Williams and Beverly Rothermel
TECH CENTER 1600/2900Filing Date:
February 13, 2001Group:
1645U.S. Patent Documents
*See Page 1*Foreign Patent Documents
*See Page 1*Other Art
*See Page 1***Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

Exam. Init.	Ref. Des.	Citation
<i>Sul</i>	C22	Loh <i>et al.</i> , "Calcineurin binds the transcription factor NFAT1 and reversibly regulates its activity," <i>J. Biol. Chem.</i> , 271:10884-10891, 1996.
<i>SWL</i>	C23	Mann <i>et al.</i> , "Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus", <i>Cell</i> , 33:153-159, 1983.
<i>SWL</i>	C24	Mao and Wiedmann, "Calcineurin enhances MEF2 DNA binding activity in calcium-dependent survival of cerebellar granule neurons," <i>J. Biol. Chem.</i> , 274:31102-31107, 1999.
<i>Sul</i>	C25	Mao <i>et al.</i> , "Neuronal activity-dependent cell survival mediated by transcription factor MEF2," <i>Science</i> , 286:785-790, 1999.
<i>Sul</i>	C26	Mesaeli <i>et al.</i> , "Calreticulin is essential for cardiac development," <i>J. Cell Biol.</i> , 144:857-868, 1999.
<i>Sul</i>	C27	Miyazaki <i>et al.</i> , "Molecular cloning of a novel thyroid hormone-responsive gene, ZAKI-4, in human skin fibroblasts," <i>J Biol Chem.</i> , 271:14567-14571, 1996.
<i>Sul</i>	C28	Molkentin <i>et al.</i> , "A calcineurin-dependent transcriptional pathway for cardiac hypertrophy," <i>Cell</i> , 93:215-228, 1998.
<i>Sul</i>	C29	Musaro <i>et al.</i> , "IGF-1 induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-ATc1," <i>Nature</i> , 400:581-585, 1999.
<i>Sul</i>	C30	Naya <i>et al.</i> , "Stimulation of slow skeletal muscle fiber gene expression by calcineurin <i>in vivo</i> ," <i>J. Biol. Chem.</i> , 275:4545-4548, 2000.
<i>Sul</i>	C31	O'Keefe <i>et al.</i> , "FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin," <i>Nature</i> , 357:692-694, 1992.
<i>Sul</i>	C32	Rothermel <i>et al.</i> , "A protein encoded within the Down syndrome critical region is enriched in striated muscles and inhibits calcineurin signaling," <i>J Biol Chem.</i> , 275:8719-8725, 2000.
<i>Sul</i>	C33	Rothermel <i>et al.</i> , "Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy <i>in vivo</i> ," <i>PNAS</i> , 98(6):3328-3333, 2001.
<i>SWL</i>	C34	Schena <i>et al.</i> , "Parallel human genome analysis: microarray-based expression monitoring of 1000 genes," <i>Proc Natl Acad Sci USA</i> , 93:10614-10619, 1996.
<i>Sul</i>	C35	Semsarian <i>et al.</i> , "Skeletal muscle hypertrophy is mediated by a Ca ²⁺ -dependent calcineurin signalling pathway," <i>Nature</i> , 400:576-581, 1999.

25030842.1

EXAMINER:

S. Williams

DATE CONSIDERED: 1-17-2003

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

RECEIVED

Page 4 of 4 JUN 22 2001

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UTSD:674US/SLH

09/782,953

TECH CENTER 1600/2900

O I P E
JUN 19 2001
PATENT & TRADEMARK OFFICE
List of Patents and Publications for Applicant's
INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

Applicant

R. Sanders Williams and Beverly Rothermel

Filing Date:

February 13, 2001

Group:

1645

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>Swl</i>	C36	Shibasaki <i>et al.</i> , "Role of kinases and the phosphatase calcineurin in the nuclear shuttling of transcription factor NF-AT4," <i>Nature</i> , 382:370-373, 1996.
<i>Swl</i>	C37	Sigal <i>et al.</i> , "Cyclophilin involved in the immunosuppressive and nephrotoxic mechanism of action of cyclosporin A?," <i>J. Exp. Med.</i> , 173:619-628, 1991.
<i>swl</i>	C38	Sun <i>et al.</i> , "Cabin 1, a negative regulator for calcineurin signaling in T lymphocytes," <i>Immunity</i> , 8:703-711, 1998.
<i>Swl</i>	C39	Sussman <i>et al.</i> , "Prevention of cardiac hypertrophy in mice by calcineurin inhibition," <i>Science</i> , 281:1690-1693, 1998.
<i>Swl</i>	C40	Wang <i>et al.</i> , "Ca ²⁺ -induced apoptosis through calcineurin dephosphorylation of BAD," <i>Science</i> , 284:339-343, 1999.
<i>swl</i>	C41	Yang <i>et al.</i> , "Independent signals control expression of the calcineurin inhibitory proteins MCIP1 and MCIP2 in striated muscles," <i>Circ. Res.</i> , 87:e61-e68, 2000.
<i>Swl</i>	C42	Youn <i>et al.</i> , "Apoptosis of T cells mediated by Ca ²⁺ -induced release of the transcription factor MEF2," <i>Science</i> , 286:790-793, 1999.
<i>Swl</i>	C43	Zhang <i>et al.</i> , "Failure of calcineurin inhibitors to prevent pressure-overload left ventricular hypertrophy in rats," <i>Circ Res.</i> , 84:722-728, 1999.
<i>swl</i>	C44	Zhuo <i>et al.</i> , "A selective role of calcineurin Aα in synaptic depotentiation in hippocampus," <i>Proc. Nat'l Acad. Sci. USA</i> , 96:4650-4655, 1999.

25030842.1

EXAMINER:

*Swl*DATE CONSIDERED: *1-17-2003*

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.